Erasca (ERAS)
NASDAQ:ERAS
Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.01
-$0.05(-2.00%)
At close: 4:00 PM EST
$19.01
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.21 - $24.28
Previous CloseN/A
Volume148.24K
Average Volume (3M)6.76M
Market Cap
$4.16B
Enterprise Value$3.99B
Total Cash (Recent Filing)$243.79M
Total Debt (Recent Filing)$45.95M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding310,984,530
10 Day Avg. Volume8,687,046
30 Day Avg. Volume6,757,213
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.72K
Enterprise Value/Ebitda-31.01
Forecast
1Y Price Target
$21.00Price Target Upside10.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.9
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ERAS-0015 Phase 1 EfficacyRobust early clinical signals—clear PK, defined pharmacologically active doses, and large ctDNA declines—reduce clinical risk versus preclinical-stage programs. Durable proof-of-concept raises the likelihood of successful pivotal design, partnership interest, and eventual commercial potential if later trials confirm responses.
Manageable Leverage / Sizable EquityLow-to-moderate leverage and substantial equity provide structural financial flexibility for a development-stage biotech. This balance-sheet profile reduces short-term refinancing pressure, supports near-term trial advancement without immediate insolvency risk, and preserves strategic optionality for partnerships or raises.
Advancing Multi-asset RAS PipelineMultiple programs advancing (ERAS-0015 and ERAS-4001) and active expansion/combination cohorts reduce binary single-asset risk. A progressing, diversified RAS-focused portfolio increases long-term value creation pathways and gives management multiple shots at clinical/regulatory success and partner interest.
Bears Say
No Commercial RevenueAs a clinical-stage company with no approved products, Erasca lacks recurring commercial cash flow. Persistent operating and net losses mean ongoing reliance on external financing to fund R&D, creating dilution risk and dependence on capital markets for sustaining development programs over the medium term.
High And Worsening Cash BurnSignificant negative operating and free cash flow, and an accelerating burn rate, materially stress runway. Even with manageable debt, sustained cash consumption will force financing, slow program timelines, or reprioritization of assets—constraining strategic choices and raising execution risk over months.
Patent And Trade-secret Legal RiskAllegations on a core asset create durable operational and commercial uncertainty. Litigation can delay trials, deter collaborators, require costly settlements or licensing, or lead to injunctive relief—each outcome could materially reduce the asset’s value and impede long-term program development.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.21 and its highest was $24.28 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $4.16B.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Aug 06, 2026 which is in 55 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on May 11, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.496.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.11.
How many shares outstanding does Erasca have?
Erasca has 310,984,530 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (10.47% Upside)
$21.00 (10.47% Upside)
Hedge Fund Trend
Increased
By 965.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
400.50%
12-Months-Change
Fundamentals
Return on Equity
-77.01%
Trailing 12-Months
Asset Growth
-2.12%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$21.00
▲(10.47% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
10.85% Insiders
11.80% Mutual Funds
55.53% Other Institutional Investors
11.22% Public Companies and
Individual Investors